1,167 results match your criteria Blood Transfusion[Journal]


Patient blood management in obstetrics: prevention and treatment of postpartum haemorrhage. A NATA consensus statement.

Blood Transfus 2019 Feb 6. Epub 2019 Feb 6.

Department of Anaesthesiology, Université de Montréal, Montreal, QC, Canada.

Patient blood management (PBM) is the timely application of evidence-informed medical and surgical concepts designed to maintain haemoglobin concentration, optimise haemostasis, and minimise blood loss in an effort to improve patient outcomes. The aim of this consensus statement is to provide recommendations on the prevention and treatment of postpartum haemorrhage as part of PBM in obstetrics. A multidisciplinary panel of physicians with expertise in obstetrics, anaesthesia, haematology, and transfusion medicine was convened by the Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis (NATA) in collaboration with the International Federation of Gynaecology and Obstetrics (FIGO), the European Board and College of Obstetrics and Gynaecology (EBCOG), and the European Society of Anaesthesiology (ESA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0245-18DOI Listing
February 2019
2 Reads

Malaria blood safety policy in five non-endemic countries: a retrospective comparison through the lens of the ABO risk-based decision-making framework.

Blood Transfus 2019 Feb 6. Epub 2019 Feb 6.

Division of Emerging and Transfusion Transmitted Diseases, FDA, Silver Spring, MD, United States of America.

Background: In non-endemic countries, malaria risk is addressed by selectively testing or deferring at-risk donors. These policy decisions were made using a variety of decision-making frameworks prior to the development of the Alliance of Blood Operators Risk Based Decision-Making Framework. It is unclear whether the range of items assessed in the decision-making process would be increased if the Framework were used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0222-18DOI Listing
February 2019
3 Reads

Effects of micronised microencapsulated ferric pyrophosphate supplementation in patients with advanced cancer and iron deficiency: a single-centre cohort pilot study.

Blood Transfus 2019 Feb 18. Epub 2019 Feb 18.

Department of Medical and Surgical Sciences and Advanced Technologies "G.F. Ingrassia", Section of Haematology, University Hospital "Policlinico-Vittorio Emanuele", University of Catania, Catania, Italy.

Background: Iron deficiency is the most common nutritional deficiency in advanced cancer patients and causes anaemia. Iron deficiency anaemia treatment (i.e. Read More

View Article

Download full-text PDF

Source
http://www.bloodtransfusion.it/articolosing.aspx?id=001007
Publisher Site
http://dx.doi.org/10.2450/2019.0181-18DOI Listing
February 2019
7 Reads

New data from the Italian National Register of Congenital Coagulopathies, 2016 Annual Survey.

Blood Transfus 2019 Feb 13. Epub 2019 Feb 13.

Department of Oncology and Molecular Medicine, Italian National Institute of Health, Rome, Italy.

Background: In Italy, the National Register of Congenital Coagulopathies (NRCC) collects epidemiological and therapeutic data from patients affected by haemophilia A (HA), haemophilia B (HB), von Willebrand's disease (vWD) and other rare coagulation disorders. Here we present data from the 2016 annual survey.

Materials And Methods: Data are provided by the Italian Haemophilia Centres, on a voluntary basis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0211-18DOI Listing
February 2019
1 Read

Viral safety of APOSEC: a novel peripheral blood mononuclear cell derived-biological for regenerative medicine.

Blood Transfus 2019 Feb 21. Epub 2019 Feb 21.

Division of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.

Background: Viral reduction and inactivation of cell-derived biologicals is paramount for patients' safety and so viral reduction needs to be demonstrated to regulatory bodies in order to obtain marketing authorisation. Allogeneic human blood-derived biological medicinal products require special attention. APOSEC, the secretome harvested from selected human blood cells, is a new biological with promising regenerative capabilities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0249-18DOI Listing
February 2019
2 Reads
2.372 Impact Factor

Transfusion-transmissible infections among Serbian blood donors: declining trends over the period 2005-2017.

Blood Transfus 2019 Feb 19. Epub 2019 Feb 19.

Institute for Medical Research, University of Belgrade, Belgrade, Serbia.

Background: The mass migrations experienced by the Western Balkans in the past decades have significantly changed the demographic structures and have probably altered the prevalence of transfusion-transmitted infections (TTIs) among blood donors. However, data on the prevalence of TTIs in the Western Balkans countries remain incomplete. This study reports the prevalence of TTIs among blood donors in Serbia in the period 2005-2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0185-18DOI Listing
February 2019
1 Read

A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.

Blood Transfus 2019 Feb 4:1-8. Epub 2019 Feb 4.

Division of Haematology and Transfusion Medicine, "Luigi Sacco" University Hospital, Milan, Italy.

Background: There is a lack of prospective clinical trials specifically designed to evaluate the benefits of prophylaxis with vWF/FVIII concentrates in patients with inherited von Willebrand disease (vWD). The aim of the study was to compare efficacy of secondary long-term prophylaxis (PRO) with vWF/FVIII in the prevention of bleeding episodes in severe vWD patients to standard of care (on-demand treatment; ODT).

Materials And Methods: In this 12-month, phase III, open-label study (PRO. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0183-18DOI Listing
February 2019
3 Reads

Multiple electrode aggregometry and thromboelastography in thrombocytopenic patients with haematological malignancies.

Blood Transfus 2018 Dec 13:1-10. Epub 2018 Dec 13.

Department of Clinical Science, University of Bergen, Norway.

Background: In thrombocytopenic patients better assessment of bleeding risk than that provided by platelet count alone is required. Multiplate aggregometry and thromboelastography (TEG) could be used, but information on their role in such patients is limited. The primary aim of this study was to investigate the feasibility of Multiplate analyses in patients with haematological malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0140-18DOI Listing
December 2018
1 Read

Intracranial haemorrhage in children and adults with haemophilia A and B: a literature review of the last 20 years.

Blood Transfus 2019 Feb 4:1-7. Epub 2019 Feb 4.

Haemophilia Centre, University Hospital of Padua, Padua, Italy.

Intracranial haemorrhage (ICH) is the most serious event in haemophiliacs, resulting in high rates of mortality and disability. Although the use of a prophylaxis regimen has improved outcomes, the mortality caused by ICH is still around 20%. ICH is more frequent at two different ages: in childhood (mostly in children aged ≤2 years) and in adulthood (with known risk factors such as hypertension and age ≥60 years). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0253-18DOI Listing
February 2019
3 Reads

Increase in post-reperfusion sensitivity to tissue plasminogen activator-mediated fibrinolysis during liver transplantation is associated with abnormal metabolic changes and increased blood product utilisation.

Blood Transfus 2019 Feb 4:1-9. Epub 2019 Feb 4.

Departments of Surgery, University of Colorado School of Medicine, Aurora, CO, United State of America.

Background: Increased systemic fibrinolytic activity can occur in liver transplant recipients after the donor graft is reperfused. However, it remains unclear whether this is related solely to tissue plasminogen activator (t-PA) levels or whether unique metabolic changes can alter t-PA activity and enhance fibrinolytic activity. We hypothesise that an increase in sensitivity to t-PA-mediated fibrinolysis (StF) following liver reperfusion is associated with specific metabolic abnormalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0205-18DOI Listing
February 2019

Telemedicine and telerehabilitation: current and forthcoming applications in haemophilia.

Blood Transfus 2019 Feb 4:1-6. Epub 2019 Feb 4.

Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, Milan, Italy.

In persons with haemophilia (PWH), the importance of comprehensive disease management to prevent bleeding, joint damage and secondary diseases has been well established. However, because haemophilia is a chronic disease, intervention programmes carried out for prolonged periods of time may create problems of patient adherence. Driven by continuous technological innovation, telemedicine is being increasingly proposed as a way to provide PWH with a range of services designed to improve their health, saving the time and cost involved in going to the treatment centre, and increasing therapeutic adherence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0218-18DOI Listing
February 2019

Position paper on laboratory testing for patients with haemophilia. A consensus document from SISET, AICE, SIBioC and SIPMeL.

Blood Transfus 2019 Feb 4:1-7. Epub 2019 Feb 4.

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Haemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0241-18DOI Listing
February 2019

Selective organ ischaemia/reperfusion identifies liver as the key driver of the post-injury plasma metabolome derangements.

Blood Transfus 2018 Dec 13:1-13. Epub 2018 Dec 13.

Department of Surgery, University of Colorado Denver, Aurora, CO, United States of America.

Background: Understanding the molecular mechanisms in perturbation of the metabolome following ischaemia and reperfusion is critical in developing novel therapeutic strategies to prevent the sequelae of post-injury shock. While the metabolic substrates fueling these alterations have been defined, the relative contribution of specific organs to the systemic metabolic reprogramming secondary to ischaemic or haemorrhagic hypoxia remains unclear.

Materials And Methods: A porcine model of selected organ ischaemia was employed to investigate the relative contribution of liver, kidney, spleen and small bowel ischaemia/reperfusion to the plasma metabolic phenotype, as gleaned through ultra-high performance liquid chromatography-mass spectrometry-based metabolomics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0188-18DOI Listing
December 2018
2 Reads

Effects of in-house cryoprecipitate on transfusion usage and mortality in patients with multiple trauma with severe traumatic brain injury: a retrospective cohort study.

Blood Transfus 2019 Jan 22:1-6. Epub 2019 Jan 22.

Department of Transfusion Medicine, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.

Background: Hypofibrinogenaemia is a common complication of multiple trauma with severe traumatic brain injury (Abbreviated Injury Scale score of the head ≥4; body ≥3). In Japan, neither fibrinogen concentrate nor cryoprecipitate is permitted to treat acquired hypofibrinogenaemia with the purpose of rapidly restoring a haemostatic level of fibrinogen. The aim of this study was to investigate transfusion usage and mortality in patients with multiple trauma and severe traumatic brain injury who were given a cryoprecipitate prepared in-house, comparing those administered the product early or later. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0198-18DOI Listing
January 2019
9 Reads

Red blood cell storage lesion: causes and potential clinical consequences.

Blood Transfus 2019 01;17(1):27-52

Department of Biochemistry and Molecular Genetics University of Colorado, Denver, CO, United States of America.

Red blood cells (RBCs) are a specialised organ that enabled the evolution of multicellular organisms by supplying a sufficient quantity of oxygen to cells that cannot obtain oxygen directly from ambient air via diffusion, thereby fueling oxidative phosphorylation for highly efficient energy production. RBCs have evolved to optimally serve this purpose by packing high concentrations of haemoglobin in their cytosol and shedding nuclei and other organelles. During their circulatory lifetimes in humans of approximately 120 days, RBCs are poised to transport oxygen by metabolic/redox enzymes until they accumulate damage and are promptly removed by the reticuloendothelial system. Read More

View Article

Download full-text PDF

Source
http://www.bloodtransfusion.it/articolo.aspx?idart=003204&am
Publisher Site
http://dx.doi.org/10.2450/2019.0217-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343598PMC
January 2019
17 Reads

Red blood cell alloimmunisation in transfusion-dependent thalassaemia: a systematic review.

Blood Transfus 2019 01;17(1):4-15

Italian National Blood Centre, National Institute of Health, Rome, Italy.

Background: Chronic red blood cell transfusion is the first-line treatment for severe forms of thalassaemia. This therapy is, however, hampered by a number of adverse effects, including red blood cell alloimmunisation. The aim of this systematic review was to collect the current literature data on erythrocyte alloimmunisation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0229-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343597PMC
January 2019
2 Reads
2.372 Impact Factor

Hitchhiker's guide to the red blood cell storage lesion.

Blood Transfus 2019 01;17(1):1-3

Department of Pathology and Cell Biology, Columbia University, New York, NY, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0257-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343593PMC
January 2019
1 Read

Fibrinogen measurement in liver disease: validation of the functional fibrinogen thromboelastography assay and a novel mathematical predictive model.

Blood Transfus 2018 Nov 9:1-10. Epub 2018 Nov 9.

Coagulation Laboratory, Department of Pathology, "Mater Dei" Hospital, Msida, Malta.

Background: Fibrinogen is produced in the liver and tends to be reduced in liver cirrhosis. Quantitative and qualitative tests exist to measure fibrinogen. We aimed to validate the functional fibrinogen thromboelastography assay (FF-TEG) and propose a new model to estimate fibrinogen levels via the Clauss method (Clauss) using data from a prothrombin time-derived fibrinogen assay (PT-Fg) in patients with liver cirrhosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0105-18DOI Listing
November 2018
5 Reads
2.372 Impact Factor

Comprehensive phenotypic and molecular investigation of RhD and RhCE variants in Moroccan blood donors.

Blood Transfus 2018 Oct 24:1-6. Epub 2018 Oct 24.

Laboratory of Haematology, Cellular and Genetic Engineering, Faculty of Medicine and Pharmacy Casablanca, Hassan II University of Casablanca, Casablanca, Morocco.

Background: To date, more than 650 (weak and partial) Rh variants have been reported. Nature and frequency of these variants are known to be ethnodependent. In transfusion medicine, their identification is important to ensure blood safety. Read More

View Article

Download full-text PDF

Source
http://www.bloodtransfusion.it/articolosing.aspx?id=000987
Publisher Site
http://dx.doi.org/10.2450/2018.0153-18DOI Listing
October 2018
19 Reads

Cost of pathogen reduction for platelets: reply to Cicchetti et al. Blood Transfus 2018; 16: 483-9.

Authors:
Albert Farrugia

Blood Transfus 2019 01 7;17(1):84. Epub 2018 Nov 7.

School of Surgery, University of Western Australia, Crawley, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0193-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343600PMC
January 2019
1 Read
2.372 Impact Factor

Identification of novel mutations in patients with fibrinogen disorders and genotype/phenotype correlations.

Blood Transfus 2018 Oct 8:1-8. Epub 2018 Oct 8.

Atherosclerosis and Thrombosis Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo (Foggia), Italy.

Background: Congenital fibrinogen disorders are caused by variants occurring within the fibrinogen gene cluster. We describe ten subjects with disease-causative variants, adding information on such disorders.

Materials And Methods: Ten subjects were referred to our Centre because of likely hypo/dysfibrinogenaemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0123-18DOI Listing
October 2018
4 Reads

Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus.

Blood Transfus 2018 Oct 24:1-10. Epub 2018 Oct 24.

Haematology Unit, Thrombosis and Haemostasis Reference Regional Center, University of Palermo, Palermo, Italy.

Background: Management of venous thromboembolism (VTE) in patients with haematologic malignancies and thrombocytopenia is clinically challenging due to the related risks. No prospective studies or clinical trials have been carried out and, therefore, no solid evidence on this compelling issue is available.

Methods: Given this, an expert panel endorsed by the Gruppo Italiano Malattie Ematologiche dell'Adulto Working Party on Thrombosis and Haemostasis was set up to produce a formal consensus, according to the RAND method, in order to issue clinical recommendations about the platelet (PLT) cut-off for safe administration of low molecular weight heparin (LMWH) in thrombocytopenic (PLT <100×10/L) adult patients with haematologic malignancies affected by acute (<1 month) or non-acute VTE. Read More

View Article

Download full-text PDF

Source
http://www.bloodtransfusion.it/articolosing.aspx?id=000986
Publisher Site
http://dx.doi.org/10.2450/2018.0143-18DOI Listing
October 2018
16 Reads

Transfused platelets enhance alloimmune responses to transfused KEL-expressing red blood cells in a murine model.

Blood Transfus 2018 Nov 7:1-10. Epub 2018 Nov 7.

Yale University School of Medicine, Department of Pediatrics, New Haven, CT, Unites States of America.

Background: Factors influencing the development of alloantibodies against blood group antigens on transfused red blood cells are poorly defined. We hypothesised that transfused platelets may act as a danger signal to recipients and affect humoral immune responses to transfused red blood cells.

Materials And Methods: Platelet-rich plasma prepared from wild-type C57BL/6 or CD40L knockout donors was transfused into wild-type or CD40L knock-out recipients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0178-18DOI Listing
November 2018
2 Reads

Prevention and management of acute reactions to intravenous iron in surgical patients.

Blood Transfus 2018 Oct 16:1-8. Epub 2018 Oct 16.

Perioperative Transfusion Medicine, Department of Surgical Specialties, Biochemistry and Immunology, School of Medicine, University of Málaga, Spain.

Absolute or functional iron deficiency is the most prevalent cause of anaemia in surgical patients, and its correction is a fundamental strategy within "Patient Blood Management" programmes. Offering perioperative oral iron for treating iron deficiency anaemia is still recommended, but intravenous iron has been demonstrated to be superior in most cases. However, the long-standing prejudice against intravenous iron administration, which is thought to induce anaphylaxis, hypotension and shock, still persists. Read More

View Article

Download full-text PDF

Source
http://www.bloodtransfusion.it/articolosing.aspx?id=000985
Publisher Site
http://dx.doi.org/10.2450/2018.0156-18DOI Listing
October 2018
22 Reads

XXV Congresso Nazionale della Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISET).

Blood Transfus 2018 Nov 7;16(Supplement no. 4):s415-s562. Epub 2018 Nov 7.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.S4DOI Listing
November 2018
2 Reads

Efficacy of platelet-rich plasma as conservative treatment in orthopaedics.

Blood Transfus 2018 11;16(6):473-474

Department of Anesthesiology Medicine, School of Medicine, University of Colorado, Aurora, Colorado, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0172-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214821PMC
November 2018
1 Read

The key role of tranexamic acid in Patient Blood Management programmes.

Blood Transfus 2018 11;16(6):471-472

Italian National Blood Centre, National Institute of Health, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0177-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214825PMC
November 2018
1 Read

Molecular genetic analysis of weak ABO subgroups in the Chinese population reveals ten novel ABO subgroup alleles.

Blood Transfus 2018 Sep 3:1-6. Epub 2018 Sep 3.

Blood Transfusion Department, Ruijin Hospital, Medical School of Shanghai, Jiao Tong University, Shanghai, China.

Background: A weak ABO subgroup is one of the most important causes of an ABO blood grouping discrepancy. Here, we investigated the distribution of weak ABO subgroups in the Chinese population and identified ten novel weak ABO subgroup alleles.

Material And Methods: We performed phenotype investigations by serological studies, analysed the DNA sequence of the ABO gene by direct sequencing or sequencing after cloning, and evaluated the role of glycosyltransferase mutations by in silico analysis and in vitro expression assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0091-18DOI Listing
September 2018
3 Reads

Influence of apheresis collection device and container on the storage properties of platelets in 90% PAS-5/10% plasma.

Blood Transfus 2018 Sep 5:1-7. Epub 2018 Sep 5.

Food and Drug Administration, CBER, Silver Spring, MD, United States of America.

Background: The storage properties of apheresis platelets suspended in the experimental additive solution PAS-5 and 10% plasma may be affected by the collection instrument or storage container.

Methods And Experimental Design: The same consenting 12 donors provided A or T platelets with concurrent plasma on four occasions in 100% plasma. Following collection and resting, the platelets were centrifuged, and plasma was expressed and resuspended in PAS-5 to yield units with 10% plasma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0136-18DOI Listing
September 2018
1 Read

Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia.

Blood Transfus 2018 11 3;16(6):525-534. Epub 2018 Sep 3.

Almar Therapeutics Pty. Ltd., Melbourne, Australia.

Selecting therapeutic products for the treatment of haemophilia follows the process of obtaining market approval of products submitted to the scrutiny of a regulatory agency. In well-resourced countries, key decisions on whether a product is sufficiently safe and of high quality are made by highly expert and well-resourced agencies, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In countries lacking such agencies, well-informed decisions can still be made through an appreciation of the key issues affecting the quality, safety and efficacy of haemophilia products. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0150-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214824PMC
November 2018
16 Reads
2.372 Impact Factor

Efficacy of topical tranexamic acid within a blood-saving programme for primary total hip arthroplasty: a pragmatic, open-label randomised study.

Blood Transfus 2018 11 3;16(6):490-497. Epub 2018 Sep 3.

Aragón Health Sciences Institute, Zaragoza, Spain.

Background: Total hip arthroplasty entails considerable peri-operative blood loss, which may lead to acute post-operative anaemia and red blood cell transfusion. This study was aimed at assessing whether the addition of topical tranexamic acid to our ongoing blood-saving protocol for total hip arthroplasty was effective and safe.

Materials And Methods: A pragmatic, prospective, open-label randomised study of patients scheduled for total hip arthroplasty at a single centre was conducted. Read More

View Article

Download full-text PDF

Source
http://www.bloodtransfusion.it/articolosing.aspx?id=000980
Publisher Site
http://dx.doi.org/10.2450/2018.0133-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214828PMC
November 2018
28 Reads

Efficacy of platelet-rich plasma as conservative treatment in orthopaedics: a systematic review and meta-analysis.

Blood Transfus 2018 11 3;16(6):502-513. Epub 2018 Sep 3.

Italian National Blood Centre, National Institute of Health, Rome, Italy.

Background: The aim of this systematic review and meta-analysis was to evaluate the benefit of platelet-rich plasma (PRP) in non-surgical orthopaedic procedures.

Material And Methods: We searched the Cochrane Wounds Specialized Register, CENTRAL, MEDLINE (through PUBMED), Embase, and SCOPUS. We also searched clinical trials registries for ongoing and unpublished studies and checked reference lists to identify additional studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0111-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214820PMC
November 2018
10 Reads
1 Citation
2.372 Impact Factor

Budget impact of implementing platelet pathogen reduction into the Italian blood transfusion system.

Blood Transfus 2018 11 3;16(6):483-489. Epub 2018 Sep 3.

Italian National Blood Centre, National Institute of Health, Rome, Italy.

Background: Despite improvements in blood donor selection and screening procedures, transfusion recipients can still develop complications related to infections by known and emerging pathogens. Pathogen reduction technologies (PRT) have been developed to reduce such risks. The present study, developed whithin a wider health technology assessment (HTA) process, was undertaken to estimate the costs of the continuing increase in the use of platelet PRT in Italy. Read More

View Article

Download full-text PDF

Source
http://www.bloodtransfusion.it/articolo.aspx?idart=003188&am
Publisher Site
http://dx.doi.org/10.2450/2018.0115-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214822PMC
November 2018
11 Reads
2.372 Impact Factor

Blood safety policy: should cautionary policies be adopted with caution?

Blood Transfus 2018 09;16(5):405-407

Bioethics Unit, Italian National Institute of Health, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0135-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125240PMC
September 2018
2 Reads

Intravenous immunoglobulin replacement treatment reduces in vivo elastase secretion in patients with common variable immune disorders.

Blood Transfus 2018 Jul 17:1-10. Epub 2018 Jul 17.

Department of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.

Background: Intravenous immunoglobulin (IVIg) treatment partially replaces antibody defects and modulates innate and adaptive immune cells in patients with primary antibody deficiencies.

Materials And Methods: This study was focused on the evaluation of the effects of in vivo IVIg administration on neutrophils from patients with common variable immune disorders (CVID). We examined polymorphonuclear neutrophil (PMN) phagocytosis, PMN oxidative burst, release of neutrophil elastase, serum level of interleukin-8 and PMN expression of CXCR1, CD11c and CD66b. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0043-18DOI Listing
July 2018
6 Reads

Experience with RHD*weak D type 4.0 in the USA.

Blood Transfus 2018 Jul 6:1-3. Epub 2018 Jul 6.

Childern's Hospital of Philadelphia, Philadelphia, PA, United States of America.

View Article

Download full-text PDF

Source
http://www.bloodtransfusion.it/articolosing.aspx?id=000976
Publisher Site
http://dx.doi.org/10.2450/2018.0114-18DOI Listing
July 2018
13 Reads

Predicting factors for liver iron overload at the first magnetic resonance in children with thalassaemia major.

Blood Transfus 2018 Jun 26:1-6. Epub 2018 Jun 26.

Rare Blood Cell Disease Unit, "Cardarelli" Hospital, Naples, Italy.

Background: Transfusion dependency determines iron overload in thalassaemia major, with devastating complications. Significant liver iron overload has been observed from early childhood and we aimed to evaluate factors that could predict liver iron overload at the first magnetic resonance imaging (MRI).

Materials And Methods: All transfusion-dependent children who underwent MRI to assess iron overload were retrospectively studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0092-18DOI Listing
June 2018
12 Reads

Prevalence, incidence and residual risk of transfusion-transmitted hepatitis C virus and human immunodeficiency virus after the implementation of nucleic acid testing in Italy: a 7-year (2009-2015) survey.

Blood Transfus 2018 09 26;16(5):422-432. Epub 2018 Jun 26.

Italian National Blood Centre, National Institute of Health, Rome, Italy.

Background: In Italy nucleic acid testing (NAT) became mandatory for hepatitis C virus (HCV) in 2002 and for human immunodeficiency virus (HIV) and hepatitis B virus in 2008. The aim of this study was to monitor the incidence and prevalence of HIV and HCV infections in Italian blood donors and the current residual risk of these infections after the introduction of NAT.

Materials And Methods: The Italian national blood surveillance system includes data from tests used to screen for transfusion-transmissible infections. Read More

View Article

Download full-text PDF

Source
http://www.bloodtransfusion.it/articolo.aspx?idart=003178&am
Publisher Site
http://dx.doi.org/10.2450/2018.0069-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125236PMC
September 2018
36 Reads

Cost-effectiveness analysis of ferric carboxymaltose in pre-operative haemoglobin optimisation in patients undergoing primary knee arthroplasty.

Blood Transfus 2018 09 26;16(5):438-442. Epub 2018 Jun 26.

Department of Orthopaedic Surgery, Hospital Clinic Barcelona, Barcelona, Spain.

Background: An analytic-decision model was built to estimate the cost-effectiveness of using ferric carboxymaltose for pre-operative haemoglobin optimisation in patients with iron deficiency anaemia undergoing primary knee arthroplasty.

Materials And Methods: We simulated 20,000 patients who were randomly assigned to the haemoglobin optimisation arm or the non-optimisation control arm in a strict 1:1 ratio. The main outcomes were cost per patient transfusion avoided and red blood cell units spared. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0031-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125239PMC
September 2018
16 Reads

Prenatal non-invasive foetal RHD genotyping: diagnostic accuracy of a test as a guide for appropriate administration of antenatal anti-D immunoprophylaxis.

Blood Transfus 2018 11 9;16(6):514-524. Epub 2018 Apr 9.

Regional Blood Centre of Emilia-Romagna, "Maggiore" Hospital, Bologna, Italy.

Background: Foetal RHD genotyping can be predicted by real-time polymerase chain reaction (qPCR) using cell-free foetal DNA extracted from maternal plasma. The object of this study was to determine the diagnostic accuracy and feasibility of non-invasive RHD foetal genotyping, using a commercial multiple-exon assay, as a guide to appropriate administration of targeted antenatal immunoprophylaxis.

Material And Methods: Cell-free foetal DNA was extracted from plasma of RhD-negative women between 11-30 weeks of pregnancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0270-17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214827PMC
November 2018
6 Reads

Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates in patients after hip or knee replacement surgery.

Blood Transfus 2018 May 11:1-6. Epub 2018 May 11.

Department of Anaesthesiology and Operative Intensive Care Medicine (CVK), Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Germany.

Background: Apixaban is a direct oral anticoagulant (DOAC) with a specific inhibition of activated factor X (FXa). In case of bleeding or need of urgent surgery a direct antidote is not yet available. Off-label application of non-specific haemostatic agents, such as prothrombin complex concentrate (PCC) and recombinant FVIIa (rFVIIa), has been reported to reverse the effects of apixaban in in vitro and animal studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0028-18DOI Listing
May 2018
8 Reads

A nationwide retrospective study on prevalence of hepatitis E virus infection in Italian blood donors.

Blood Transfus 2018 09 4;16(5):413-421. Epub 2018 May 4.

Italian National Blood Centre, National Institute of Health, Rome, Italy.

Background: In Europe, hepatitis E virus (HEV) infection is mainly a food-borne zoonosis, but it can also be transmitted by blood transfusion. It is usually a mild and self-limited infection. However, immunocompromised persons, who are also those more likely to undergo blood transfusions, may develop chronic hepatitis and often cirrhosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0033-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125237PMC
September 2018
10 Reads

Haemolysis index for the screening of intravascular haemolysis: a novel diagnostic opportunity?

Blood Transfus 2018 09 8;16(5):433-437. Epub 2018 May 8.

Department of Haematology and Transfusion Medicine, "Carlo Poma" Hospital, Mantua, Italy.

The diagnostic approach to patients with intravascular haemolysis remains challenging, since no first-line laboratory test seems to be entirely suitable for the screening of this condition. Recent evidence shows that an enhanced cell-free haemoglobin (fHb) concentration in serum or plasma is a reliable marker of red blood cell injury, and may also predict clinical outcomes in patients with different forms of haemolytic anaemias. However, the routine use of the haemiglobincyanide assay, the current reference method for measuring fHb, seems unsuitable for a timely diagnosis of intravascular haemolysis, for many safety and practical reasons. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0045-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125234PMC
September 2018
4 Reads

Safety and efficacy of tranexamic acid for prevention of obstetric haemorrhage: an updated systematic review and meta-analysis.

Blood Transfus 2018 07 3;16(4):329-337. Epub 2018 Apr 3.

Italian National Blood Centre, National Institute of Health, Rome, Italy.

Background: A number of clinical systematic review and meta-analysis have been published on the use of tranexamic in the obstetric setting. The aim of this meta-analysis was to evaluate the safety and effectiveness of tranexamic acid in reducing blood loss when given prior to caesarean delivery.

Materials And Methods: We searched the Cochrane Wounds Specialized Register, Cochrane Central, MEDLINE (through PUBMED), Embase, and SCOPUS electronic databases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0026-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034773PMC
July 2018
24 Reads
1 Citation
2.372 Impact Factor

Red blood cell salvage analysis from clotted blood.

Blood Transfus 2018 Apr 4:1-5. Epub 2018 Apr 4.

Department of Anesthesiology, Magee Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA, United States of America.

Background: Blood clots discovered within body cavities intra-operatively are often manually broken up and placed in an autotransfusion device to recover autologous blood cells. This study evaluated the efficiency at which these red blood cells can be recovered from clot and to determine if these cells would be free of fibrin and clumping which might pose a risk of micro-emboli.

Materials And Methods: Whole blood was aliquoted into 25 mL volume samples. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2018.0008-18DOI Listing
April 2018
4 Reads